Integration Of Bioreason Classpharmer™ Suite And Spotfire Decisionsite™ For Lead Discovery Announced
Bioreason, Inc., a cheminformatics software and service provider, announced the release of the latest version of ClassPharmer Suite for Screening Data Analysis, Hit-to-Lead Development, Lead Optimization, and Predictive Toxicology. Bioreason has worked together with Spotfire®, the market leader in visual analytic applications for drug discovery, to integrate their technologies in this new release.
Dr. Andrew DePristo, President and CEO of Bioreason, stated, “This new version brings the ease-of-use of DecisionSite® to ClassPharmer and makes Bioreason’s proprietary algorithms for analysis of chemical classes available to users of Spotfire’s DecisionSite for Lead Discovery. The integration of these two programs gives pharmaceutical and biotech companies better, faster decision-making capabilities. For example, the optimization of compounds for multiple competing properties can be accelerated by the unique combination of class based reasoning and advanced visual analysis tools.”
“Many pharmaceutical companies employ Spotfire’s DecisionSite visual analytics applications across their entire spectrum of research operations,” said Christopher Ahlberg, Ph.D., CEO of Spotfire. “The integration with ClassPharmer will provide them an opportunity to improve productivity during lead optimization and increase the probability of finding drug leads.”
The two companies sponsored a webcast on June 22, 2005, titled “Lead Optimization Using Spotfire DecisionSite and Bioreason ClassPharmer Suite”. This webcast illustrated the ease with which the two products can be used as an integrated platform for the analysis of screening data and as a mechanism for deriving additional information related to selectivity during lead optimization. Individuals can replay this event: http://www.spotfire.com/events/webcasts/detail.cfm?id=6007
Bioreason, Inc., is headquartered in Santa Fe, New Mexico, with sales and support offices in Strasbourg (France) and is represented by CTC Laboratory Systems in Japan. Bioreason provides knowledge-based software, services, and collaborations that help increase the success of the hits-to-leads-to-clinic process in drug discovery. For information on the company see: http://www.bioreason.com
Spotfire, Inc. ( http://www.spotfire.com ) provides interactive, visual data analytics applications and services that empower enterprises and their end-users to improve operational performance and gain an information advantage over the competition.
Spotfire and DecisionSite are registered trademarks of Spotfire, Inc. Other company or product names may be the trademarks of their respective owners.
